Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma

References

• Banks P M, Warnke R A. Mediastinal (thymic) large B-cell lymphoma. World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues, E Jaffe, N Harris, H Stein, J Vardiman. IARC Press, Lyon 2001; 175–178
   Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Isaacson P G, Norton A J, Addis B J. The human thymus contains a novel population of B lymphocytes. Lancet 1987; 2: 1488–1491
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R D, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851–862
   PubMed Web of Science ®Google Scholar
• Savage K J, Monti S, Kutok J L, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871–3879
   PubMed Web of Science ®Google Scholar
• Haioun C, Gaulard P, Roudot-Thoraval F, Divine M, Jouault H, Lebourgeois J P, et al. Mediastinal diffuse large-cell lymphoma with sclerosis: a condition with a poor prognosis. Am J Clin Oncol 1989; 12: 425–429
   PubMed Web of Science ®Google Scholar
• Lavabre-Bertrand T, Donadio D, Fegueux N, Jessueld D, Taib J, Charlier D, et al. A study of 15 cases of primary mediastinal lymphoma of B-cell type. Cancer 1992; 69: 2561–2566
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, Boveri E, Morra E, Brusamolino E, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993; 11: 2306–2313
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, Strater J, Klersy C, Gianelli U, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997; 15: 1646–1653
   PubMed Web of Science ®Google Scholar
• Todeschini G, Ambrosetti A, Meneghini V, Pizzolo G, Menestrina F, Chilosi M, et al. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients. J Clin Oncol 1990; 8: 804–808
   PubMed Web of Science ®Google Scholar
• Cazals-Hatem D, Lepage E, Brice P, Ferrant A, d'Agay M F, Baumelou E, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d'Etude des Lymphomes de l'Adulte”) study. Am J Surg Pathol 1996; 20: 877–888
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Martelli M, Magagnoli M, Pescarmona E, Scaramucci L, Palombi F, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67) Gallium scan in 50 patients. Blood 1999; 94: 3289–3293
   PubMed Web of Science ®Google Scholar
• Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004; 90: 372–376
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Martelli M, Bertini M, Gianni A M, Devizzi L, Federico M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002; 87: 1258–1264
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Cairoli R, Grillo G, Tedeschi A, Gargantini L, Marenco P, Tresoldi E, et al. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. Bone Marrow Transplant 2002; 29: 473–477
   PubMed Web of Science ®Google Scholar
• Sehn L H, Antin J H, Shulman L N, Mauch P, Elias A, Kadin M E, et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998; 91: 717–723
   PubMed Web of Science ®Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Velasquez W S, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Rodriguez-Monge E J, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 1997; 11: 937–947
   PubMed Web of Science ®Google Scholar
• Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004; 101: 1835–1842
   PubMed Web of Science ®Google Scholar
• Girouard C, Dufresne J, Imrie K, Stewart A K, Brandwein J, Prince H M, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 1997; 8: 675–680
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Mollee P, Pereira D, Nagy T, Song K, Saragosa R, Keating A, Crump M. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant 2002; 30: 273–278
   PubMed Web of Science ®Google Scholar
• Weaver C H, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969
   PubMed Web of Science ®Google Scholar
• Gopal A K, Gooley T A, Golden J B, Maloney D G, Bensinger WI, Petersdorf S H, et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001; 27: 593–599
   PubMed Web of Science ®Google Scholar
• Watts M J, Sullivan A M, Leverett D, Peniket A J, Perry A R, Williams C D, et al. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol 1998; 16: 1554–1560
   PubMed Web of Science ®Google Scholar
• Schwella N, Beyer J, Schwaner I, Heuft H G, Rick O, Huhn D, et al. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol 1996; 14: 1114–1121
   PubMed Web of Science ®Google Scholar
• Kiss J E, Rybka W B, Winkelstein A, deMagalhaes-Silverman M, Lister J, D'Andrea P, et al. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 303–310
   PubMed Web of Science ®Google Scholar
• Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794
   PubMed Web of Science ®Google Scholar
• Vose J M, Zhang M J, Rowlings P A, Lazarus H M, Bolwell B J, Freytes C O, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406–413
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Nimer S D, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102: 53–59
   PubMed Web of Science ®Google Scholar
• Guiter C, Dusanter-Fourt I, Copie-Bergman C, Boulland M L, Le Gouvello S, Gaulard P, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 2004; 104: 543–549
   PubMed Web of Science ®Google Scholar
• Feuerhake F, Kutok J L, Monti S, Chen W, LaCasce A S, Cattoretti G, et al. NF-κB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106: 1392–1399
   PubMed Web of Science ®Google Scholar
• Sunwoo J B, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419–1428
   PubMed Web of Science ®Google Scholar
• Lam L T, Davis R E, Pierce J, Hepperle M, Xu Y, Hottelet M, et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005; 11: 28–40
   PubMed Web of Science ®Google Scholar
• Savage K J, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne R D, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006; 17: 123–130
   PubMed Web of Science ®Google Scholar
• Vellenga E, van Putten W L, van 't Veer M B, Zijlstra J M, Fibbe W E, van Oers M H, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008; 111: 537–543
   PubMed Web of Science ®Google Scholar